RxDoctor Payments Data

Rene Elkin, MD

Neurology · Bronx, NYNPI 1962592378

Payments from drug & device makers

$185,949in general payments, 2019–2025

Across 215 payments — averaging $864.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$81K
  • Biogen$48K
  • TG Therapeutics, Inc.$26K
  • Bristol Myers Squibb$23K
  • Genentech USA, Inc.$4K
  • Greenwich Biosciences, Inc.$2K
  • plus $949 from 10 others

What the payments were for

  • Consulting fees$19,42510%
  • Speaking & faculty fees$156,75384%
  • Travel & lodging$4,8663%
  • Food & beverage$4,6573%
  • Education$2500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$185,949 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$10,320
Medicare patients
79
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a15$181,847
AubagioTeriflunomide12$143,099
VumerityDiroximel Fumarate12$89,683
GlatopaGlatiramer Acetate19$42,990
Teriflunomide12$12,570
Dalfampridine ErDalfampridine28$11,312
Lacosamide61$5,462
Levetiracetam76$4,674
Carbamazepine ErCarbamazepine12$1,812
Tizanidine Hcl22$1,501
Baclofen58$1,289
Gabapentin65$998
Memantine Hcl48$840
Carbamazepine16$770
Phenytoin Sodium Extended31$754

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack), Vumerity$48,270$271,53027 claims
SanofiAubagio$81,008$143,09912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →